You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BRCA 1

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Germline Variant Carriers With BRCA1 or BRCA2

Recruiting
  • BRCA1 and/or BRCA2 Variant Carriers
  • +3 more
    • Okayama, Japan
      Okayama University
    Dec 25, 2022

    Breast Cancer, Ovarian Cancer, Pancreas Cancer Trial (TNG348, Olaparib)

    Not yet recruiting
    • Breast Cancer
    • +7 more
    • (no location specified)
    Sep 26, 2023

    PREDICTION OF GERMLINE BRCA 1/2 GENES FROM HEALTHY OVARIES

    Not yet recruiting
    • BRCA Mutation
    • +2 more
    • Germinal BRCA
    • (no location specified)
    Mar 3, 2023

    Ultra-rapid BRCA1/2 Status Screening Test in Theranostic

    Not yet recruiting
    • Breast Cancer
    • Questionnaires
    • Communication of the results of the BRCA1/2 ultra rapid test
    • (no location specified)
    Oct 26, 2023

    Breast Cancer, Genetic Predisposition Trial in Rome, Varese (Genetic predisposition to breast cancer)

    Recruiting
    • Breast Cancer
    • Genetic Predisposition
    • Genetic predisposition to breast cancer
    • Rome, Italy
    • +1 more
    May 4, 2023

    Breast Cancer, Ovarian Cancer, Breast Tumors Trial in Dnipro, Kyiv (Axitinib)

    Enrolling by invitation
    • Breast Cancer
    • +7 more
    • Dnipro, Ukraine
    • +1 more
    Jun 17, 2023

    Breast Cancer, Metastatic Breast Cancer, BRCA1 Gene Mutation Trial in Boston (ABT-888, temozolomide)

    Active, not recruiting
    • Breast Cancer
    • +3 more
    • Boston, Massachusetts
    • +2 more
    Dec 21, 2022

    BRCA1/2 Flu Vaccine

    Active, not recruiting
    • BRCA1 Mutation
    • BRCA2 Mutation
    • Seasonal influenza vaccine
    • Philadelphia, Pennsylvania
      University of Pennsylvania
    Aug 16, 2022

    BRCA and NACT in TNBC Patients

    Completed
    • Triple-Negative Breast Cancer
    • BRCA1/2 genetic testing
    • Rome, RM, Italy
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Feb 20, 2023

    Triple Negative Breast Tumors, Triple Negative Breast Cancer, Breast Tumors Trial (Pembrolizumab, Paclitaxel, Carboplatin)

    Not yet recruiting
    • Triple Negative Breast Neoplasms
    • +7 more
    • (no location specified)
    Aug 1, 2022

    BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer Trial in Providence (Talazoparib Oral Capsule)

    Active, not recruiting
    • BRCA1 Mutation
    • +4 more
    • Talazoparib Oral Capsule
    • Providence, Rhode Island
    • +1 more
    Nov 30, 2022

    Breast Cancer BRCA1 Carriers: a Pilot Study

    Withdrawn
    • BRCA1 Mutation
    • +2 more
    • Mifepristone 200 MG
    • Prophylactic mastectomy
    • Carmel, Indiana
    • +1 more
    Dec 13, 2022

    BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma Trial in Buffalo, New York (biological, other, drug)

    Active, not recruiting
    Has Results
    • BRCA1 Gene Mutation
    • +5 more
    • Durvalumab
    • +3 more
    • Buffalo, New York
    • +1 more
    Jan 20, 2023

    Quality of Life Post Salpingo-oophorectomy in BRCA1/2 & PALB2

    Recruiting
    • Hereditary Breast and Ovarian Cancer
      • Barcelona, Spain
        Hospital de la Santa Creu i Sant Pau
      Jun 3, 2022

      Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation Trial (Olaparib, LHRH agonist)

      Not yet recruiting
      • Prostate Cancer
      • +4 more
      • (no location specified)
      Aug 10, 2022

      Breast Cancer After Ovarian Cancer During and/or After Therapy:

      Recruiting
      • BRCA-Associated Breast Carcinoma
      • Next-generation sequencing (NGS) assay TruSight Oncology 500 (TSO 500).
      • Rome, RM, Italy
        Fondazione Policlinico Universitario Agostino Gemelli IRCCS
      Mar 9, 2023

      Breast Cancer Trial in Tucson, Albuquerque (Pegylated liposomal doxorubicin)

      Completed
      • Breast Cancer
      • Pegylated liposomal doxorubicin
      • Tucson, Arizona
      • +1 more
      Jan 9, 2023

      Endocrine Disruptors and Life STILe in Breast Cancer Development

      Recruiting
      • Breast Cancer
      • +5 more
        • Roma, Italy
          Alessandra Fabi
        Feb 25, 2023

        Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation Trial in San Francisco (Niraparib, Irinotecan)

        Not yet recruiting
        • Metastatic Solid Tumor
        • +4 more
        • San Francisco, California
          University of California, San Francisco
        Jan 12, 2023

        Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma Trial (Nab paclitaxel,

        Not yet recruiting
        • Pancreatic Acinar Cell Carcinoma
        • +6 more
        • Nab paclitaxel
        • +5 more
        • (no location specified)
        Oct 30, 2023

        Advanced Malignant Tumor, ATM Gene Mutation, BRCA1 Gene Mutation Trial in Houston (Laboratory Biomarker Analysis,

        Active, not recruiting
        • Advanced Malignant Neoplasm
        • +7 more
        • Laboratory Biomarker Analysis
        • +2 more
        • Houston, Texas
          M D Anderson Cancer Center
        Feb 21, 2022

        Metastatic Castration-resistant Prostate Cancer Trial in Guangzhou (Pamiparib)

        Recruiting
        • Metastatic Castration-resistant Prostate Cancer
        • Guangzhou, Guangdong, China
          Sun Yat-sen University Cancer Center
        Apr 7, 2022

        Women With Mutations in the Breast Cancer Susceptibility Genes BRCA1,2 Trial in Stockholm (Mifepristone)

        Completed
        • Women With Mutations in the Breast Cancer Susceptibility Genes BRCA1,2
        • Stockholm, Sweden
          Department of Woman and Child Health Karolinska University Hospi
        Jan 15, 2022

        Hereditary Breast and Ovarian Cancer Trial in Cologne, Kiel, Munich (Structured exercise training plus mediterranean diet)

        Active, not recruiting
        • Hereditary Breast and Ovarian Cancer
        • Structured exercise training plus mediterranean diet
        • Cologne, Germany
        • +2 more
        Oct 25, 2022

        Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer Trial in Stanford (Talazoparib Tosylate)

        Active, not recruiting
        • Advanced Breast Cancer
        • +2 more
        • Talazoparib Tosylate
        • Stanford, California
          Stanford University Hospitals and Clinics
        Nov 16, 2022